May 30, 2024 Press Releases
PDF Version AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients to support its use as an immunotherapy in patients...
Oct 17, 2022 Press Releases
PDF Version SAN FRANCISCO, Calif. – October 17, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the first subject has been dosed in...
Sep 6, 2022 Press Releases
PDF Version AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleen AT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrils AT-02 binds potently to multiple types of amyloid including ATTR, AL, and ALECT2 SAN FRANCISCO, Calif....
